Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

Overview of Castleman disease

Angela Dispenzieri, David C. Fajgenbaum

Blood (2020) 135 (16): 1353–1364.

https://doi.org/10.1182/blood.2019000931

Published: 2020

Journal Articles

Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Marie José Kersten, MD PhD, Monique C. Minnema, Josephine M. Vos, MD PhD, Kazem Nasserinejad, Marcel Kap, BSc, Eftathios Kastritis, Maria Gavriatopoulou, MD, Martine E.D. Chamuleau, Dries Deeren, MD PhD, Lidwine Winnifred Tick, MD PhD, Jeanette K. Doorduijn, MD PhD, Fritz Offner, MD, Lara H Bohmer, MD, Karima Amaador, MD, Roberto D Liu, BSc, Steven T Pals, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 344.

https://doi.org/10.1182/blood-2019-122365

Published: 2019

Journal Articles

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Zunairah Shah, MBBS, Mustafa Nadeem Malik, MD, Syeda Sabeeka Batool, MBBS, MD, Sravanthi Kotapati, MBBS, Aisha Akhtar, MBBS, Owais ur Rehman, MBBS, Marium Ghani, MBBS, Maryam Sadiq, MBBS, Arshia Akbar, MD, Aqsa Ashraf, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Hafiz Muhammad Fazeel, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5567.

https://doi.org/10.1182/blood-2019-129652

Published: 2019

Journal Articles

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Sarah R Brown, PhD MSc, BSc, Andrew Hall, Jessica Kendall, BSc, MSc, Emma Ingleson, Louise Flanagan, PhD, Holger W Auner, MD PhD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Mamta Garg, MD FRCP, FRCPath, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 5552.

https://doi.org/10.1182/blood-2019-123672

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome

Blood (2019) 134 (Supplement_1): 1846.

https://doi.org/10.1182/blood-2019-127366

Published: 2019

Journal Articles

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Barbara Jeker, Sarah Farag, Urban Novak, Ulrike Bacher, Behrouz Mansouri Taleghani, Qiyu Li, Thomas Pabst, MD

Blood (2019) 134 (Supplement_1): 1963.

https://doi.org/10.1182/blood-2019-127848

Published: 2019

Journal Articles

POEMS Syndrome: A Review of Our Patient Population

Simran Arora Elder, MD BA, Mehmet Hakan Kocoglu, MD

Blood (2019) 134 (Supplement_1): 5516.

https://doi.org/10.1182/blood-2019-123414

Published: 2019

Journal Articles

Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

Michele Cavo, Valerio De Stefano, MD, Angel Ramirez Payer, Martin Wiesholzer, Yvonne Tromp, Gaëtan Vanstraelen, Baerbel Schaedlich, Richez Valentine, Sujith Dhanasiri, Elisabeth Kueenburg, Barbara Rosettani, Claire Martin, Stefano Pozzi, Pamela Bacon, Barbara Gamberi

Blood (2019) 134 (Supplement_1): 5580.

https://doi.org/10.1182/blood-2019-124555

Published: 2019

Journal Articles

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Zara Sayar, MD FRCPath, MRCP, Anna Weatherill, Stephen Keddie, Jonathan Sive, MD, Michael P Lunn, Mari Thomas, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 714.

https://doi.org/10.1182/blood-2019-125639

Published: 2019

Journal Articles

Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center

Katie Stone, BS, Francisco Socola, MD, Amy Greenway, Samina Waheed, Kristen Carter, APRN, Diane Glendinning, APRN, Daisy Alapat, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 3701.

https://doi.org/10.1182/blood-2018-99-119510

Published: 2018

Journal Articles

Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Patients: Single Institutional Experience

Reyad Dada, MD, Aisha Alharbi, MD, Ehab Mosaaf, MD

Blood (2018) 132 (Supplement 1): 5356.

https://doi.org/10.1182/blood-2018-99-110262

Published: 2018

Journal Articles

Neurological Adverse Events Determine Morbidity and Mortality Post Allogeneic Hematopoietic Cell Transplantation

Ioanna Sakellari, Eleni Gavriilaki, MD, Sotirios Papagiannopoulos, Maria Gavriilaki, MD, Ioannis Batsis, Despina Mallouri, Anna Vardi, MD PhD, Varnavas Constantinou, Michalis Iskas, Marianna Masmanidou, Evangelia Yannaki, MD, Triantafyllos Geroukis, MD, Dimitrios Kazis, Vasilis Kimiskidis, Achilles Anagnostopoulos

Blood (2018) 132 (Supplement 1): 5732.

https://doi.org/10.1182/blood-2018-99-112032

Published: 2018

Journal Articles

Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study

Max S. Topp, Johannes Duell, MD, Gerhard Zugmaier, Michel Attal, Philippe Moreau, Christian Langer, Jan Kroenke, MD, Thierry Facon, Hermann Einsele, Gerd Munzert, MD

Blood (2018) 132 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2018-99-109769

Published: 2018

Journal Articles

Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Aaron Yarlas, PhD, Giampaolo Merlini, MD, Michelle K White, PhD, Asia Sikora Kessler, PhD, Andrew Lovley, MA, Spencer D Guthrie, MPH, MBA, Michael Pollock, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2018-99-119578

Published: 2018

Journal Articles

Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis

Thomas Brannagan, Annabel K. Wang, Teresa Coelho, Marcia Waddington Cruz, Michael J. Polydefkis, Peter J. Dyck, Violaine Plante-Bordeneuve, John L. Berk, Fabio Barroso, Giampaolo Merlini, Isabel Conceição, Steven G. Hughes, Jesse G. Kwoh, Shiangtung W. Jung, Spencer Guthrie, Michael Pollock, Merrill D. Benson, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 498.

https://doi.org/10.1182/blood-2018-99-116995

Published: 2018

Journal Articles

Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Aaron Yarlas, PhD, Giampaolo Merlini, MD, Michelle K White, PhD, Asia Sikora Kessler, PhD, Andrew Lovley, MA, Spencer D Guthrie, MPH, MBA, Michael Pollock, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 4803.

https://doi.org/10.1182/blood-2018-99-119216

Published: 2018

Journal Articles

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Jessica Chung, PhD MPH, Damion Nero, PhD, Bruce Feinberg, DO, Jonathan Kish, PhD MPH, Chadi Nabhan, MD MBA, FACP

Blood (2017) 130 (Supplement 1): 3449.

https://doi.org/10.1182/blood.V130.Suppl_1.3449.3449

Published: 2017

Journal Articles

Unusual Long Term Remission in Multiple Myeloma Using Conventional Therapy Combined with Danazol

Matthew P Salzberg, MD, Pamela B. Dudkiewicz, DNP, ARNP, Lawrence L. Horstman, BS, Wenche Jy, PhD, Yeon S. Ahn, MD

Blood (2017) 130 (Supplement 1): 5423.

https://doi.org/10.1182/blood.V130.Suppl_1.5423.5423

Published: 2017

Journal Articles

First Report on a Successful Screening Program for MYC Rearrangements and a Prospective Clinical Trial Based on MYC Rearrangement in Newly Diagnosed DLBCL Patients in the Netherlands

Martine Chamuleau, MD PhD, Marcel Nijland, MD, Niek Lamers, Nathalie Hijmering, Dana Chitu, Josée Zijlstra, MD, Otto Visser, MDPhD, Josephine M. Vos, MD, Henriette Berenschot, MD, Rinske Boersma, MD, Marie Jose Kersten, MD PhD, Daphne de Jong, Prof Dr

Blood (2017) 130 (Supplement 1): 4144.

https://doi.org/10.1182/blood.V130.Suppl_1.4144.4144

Published: 2017

NARROW

Overview of Castleman disease

Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

POEMS Syndrome: A Review of Our Patient Population

Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center

Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Patients: Single Institutional Experience

Neurological Adverse Events Determine Morbidity and Mortality Post Allogeneic Hematopoietic Cell Transplantation

Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis

Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Unusual Long Term Remission in Multiple Myeloma Using Conventional Therapy Combined with Danazol

First Report on a Successful Screening Program for MYC Rearrangements and a Prospective Clinical Trial Based on MYC Rearrangement in Newly Diagnosed DLBCL Patients in the Netherlands

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only